Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9

British Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2008, Pages 893-907

  Jiao, Zheng ^a,b   Ding, Jun Jie ^a   Shen, Jie ^a   Liang, Hui Qi ^b   Zhong, Long Jin ^b   Wang, Yi ^b   Zhong, Ming Kang ^b   Lu, Wei Yue ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Enterohepatic circulation; Mycophenolic acid; Population pharmacokinetics; UGT1A9

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; COMPARTMENT MODEL; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; GENE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POPULATION MODEL; PRIORITY JOURNAL; UGT1A9 GENE;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; ENTEROHEPATIC CIRCULATION; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; POLYMORPHISM, GENETIC; STATISTICS AS TOPIC;

EID: 43549110010     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03109.x     Document Type: Article

References (63)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996 61: 1029 37.
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 345: 1321 5.
3. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995 60: 225 32.
4. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996 28: 925 9.
5. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol 1999 51: 1143 8.
6. Cremers S, Schoemaker R, Scholten E, den Hartigh J, Konig-Quartel J, van Kan E, Paul L, de Fijter J. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 2005 60: 249 56.
7. Premaud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y, Hoizey G, Le Guellec C, Marquet P. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 2005 44: 837 47.
8. Jiao Z, Shen J, Zhong LJ, Yu YQ, Zhong MK. Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid. Acta Pharmceutica Sinica 2006 41: 272 6.
9. Jacquez JA. Parameter identifiability is required in pooled data methods. J Pharmacokinet Biopharm 1996 24: 301 5.
10. Bellman R, Astrom KJ. On structural identifiability. Math Biosic 1970 7: 329 39.
11. Evans ND, Godfrey KR, Chapman MJ, Chappell MJ, Aarons L, Duffull SB. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Pharmacodyn 2001 28: 93 105.
12. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 2002 41: 751 90.
13. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007 46: 13 58.
14. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998 34: 429 55.
15. van Gelder T, Meur YL, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28: 145 54.
16. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004 32: 775 8.
17. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004 14: 501 15.
18. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 2005 33: 139 46.
19. Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos 2006 34: 1539 45.
20. Miles KK, Kessler FK, Smith PC, Ritter JK. Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos 2006 34: 1632 9.
21. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004 14: 329 32.
22. Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005 78: 351 61.
23. Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H, Habuchi T, Suzuki T. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007 63: 279 88.
24. Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K, Kaniwa N, Komamura K, Kotake T, Morishita H, Kamakura S, Kitakaze M, Tomoike H, Shirao K, Tamura T, Yamamoto N, Kunitoh H, Hamaguchi T, Yoshida T, Kubota K, Ohtsu A, Muto M, Minami H, Saijo N, Kamatani N, Sawada JI. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006 6: 63 75.
25. Jiao Z, Zhong Y, Shen J, Yu YQ. Simple high-performance liquid chromatographic assay, with post-column derivatization, for simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. Chromatographia 2005 62: 363 71.
26. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005 15: 97 8.
27. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 58: 51 64.
28. Boeckmann AJ, Sheiner LB, Beal S. NONMEM Users Guide. San Francisco: University of California: NONMEM project group, 1994-2006.
29. Bonate PL. Nonlinear mixed effects models: practical issues. In: Pharmacokinetic-Pharmacodynamic Modeling and Simulation, 1st edn, ed. Bonate PL. New York: Springer Science and Buisness Media, 2005 267 72.
30. Hooker AC, Staatz CE, Karlsson MO. Conditional Weighted Residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007 24: 2187 97.
31. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995 12: 1845 55.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16: 31 41.
33. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992 20: 511 28.
34. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 9: 503 12.
35. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001 28: 171 92.
36. Gabrielsson J, Weiner D. Enterohepatic recirculation. In: Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 3rd edn, eds Gabrielsson J, Weiner D. Stockholm: Swedish Pharmaceutical Press, 2000 633 8.
37. Wahlby U, Bouw MR, Jonsson EN, Karlsson MO. Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 2002 29: 251 69.
38. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001 28: 231 52.
39. Pescovitz MD, Guasch A, Gaston R, Rajagopalan P, Tomlanovich S, Weinstein S, Bumgardner GL, Melton L, Ducray PS, Banken L, Hall J, Boutouyrie BX. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003 3: 1581 6.
40. van Gelder T, Smak Gregoor PJ, Weimar W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 2000 22: 639.
41. Hesselink DA, van Hest RM, Mathot RA, Bonthuis F, Weimar W, de Bruin RW, van Gelder T. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005 5: 987 94.
42. Kobayashi M, Saitoh H, Kobayashi M, Tadano K, Takahashi Y, Hirano T. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004 309: 1029 35.
43. Jiao Z, Zhong JY, Zhang M, Shi XJ, Yu YQ, Lu WY. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 2007 63: 27 37.
44. Liang MZ, Lu YP, Nan F, Yu Q, Qin YP, Zou YG. Pharmacokinetics of mycophenolic acid after a single and multiple oral doses of mycophenolate mofetil in Chinese renal transplant recipients. Transplant Proc 2004 36: 2065 7.
45. Lu XY, Huang HF, Sheng-Tu JZ, Liu J. Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. J Zhejiang Univ Sci B 2005 6: 885 91.
46. Liang MZ, Lu YP, Nan F, Li YP. Pharmacokinetics of mycophenolic acid and its glucuronide after a single and multiple oral dose of mycophenolate mofetil in Chinese renal transplantation recipients. Transplant Proc 2006 38: 2044 7.
47. Cho EK, Han DJ, Kim SC, Burckart GJ, Venkataramanan R, Oh JM. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol 2004 44: 743 50.
48. van Hest RM, Mathot RA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T. Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 2006 17: 871 80.
49. Arizon del Prado JM, Aumente MD, Lopez Granados A, Siles JR, Paulovic D, Romo E, Concha M, Vallés F, Casares J, Muñoz I, Segura C, Muñoz MI. Use of mycophenolate mofetil in patients with transplanted heart and renal insufficiency: the relevance of the pharmacokinetic study. Transplant Proc 2002 34: 144 5.
50. Gonzalez-Roncero FM, Gentil MA, Brunet M, Algarra G, Pereira P, Cabello V, Peralvo M. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc 2005 37: 3749 51.
51. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000 22: 27 30.
52. Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 1998 63: 512 8.
53. van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, Mathot RA. Time-dependent clearance of mycophenolic acid in renal transplant recipients. Br J Clin Pharmacol 2007 63: 741 52.
54. Atcheson BA, Taylor PJ, Kirkpatrick CM, Duffull SB, Mudge DW, Pillans PI, Johnson DW, Tett SE. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004 26: 284 6.
55. Picard N, Premaud A, Rousseau A, Le Meur Y, Marquet P. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 2006 62: 477 84.
56. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000 14: 100 4.
57. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999 21: 536 9.
58. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997 5: 225 32.
59. Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007 81: 392 400.
60. Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH, Wright C, Badner J, Pei D, Boyett JM, Cook E Jr., Ratain MJ. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003 73: 566 74.
61. Miles KK, Stern ST, Smith PC, Kessler FK, Ali S, Ritter JK. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 2005 33: 1513 20.
62. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006 82: 1074 84.
63. Wada K, Takada M, Kotake T, Ochi H, Morishita H, Komamura K, Oda N, Mano A, Kato TS, Hanatani A, Nakatani T. Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. Circ J 2007 71: 1022 8.